Swiss All Share Index

Swiss All Share Index handeln
17.704,72 PKT -266,25 PKT -1,48 %
finanzen.net zero
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

ISIN CH0009111011


Analysen zu Swiss All Share Index-Werten

Datum Rating Analyst
27.01.12 UBS underperform Exane-BNP Paribas SA
27.01.12 Holcim sell Citigroup Corp.
27.01.12 Logitech neutral Citigroup Corp.
27.01.12 Novartis outperform Credit Suisse Group
27.01.12 Novartis buy Société Générale Group S.A. (SG)
26.01.12 Zurich Insurance halten Independent Research GmbH
26.01.12 Logitech neutral Sarasin Research
26.01.12 Novartis underperform Cheuvreux SA
25.01.12 Holcim neutral UBS AG
25.01.12 Novartis buy WestLB AG
25.01.12 Novartis halten Independent Research GmbH
25.01.12 Novartis buy Sarasin Research
25.01.12 Lonza neutral Sarasin Research
25.01.12 SGS SA hold Société Générale Group S.A. (SG)
24.01.12 Kühne + Nagel International buy Citigroup Corp.
24.01.12 Novartis buy Sarasin Research
24.01.12 Novartis outperform Sanford C. Bernstein and Co., Inc.
23.01.12 Zurich Insurance neutral Exane-BNP Paribas SA
23.01.12 Novartis buy Nomura
20.01.12 ams-OSRAM kaufen Erste Bank AG
20.01.12 Givaudan reduce Nomura
20.01.12 Novartis buy Nomura
20.01.12 Swiss Re neutral Nomura
20.01.12 Swiss Re hold Société Générale Group S.A. (SG)
20.01.12 Novartis overweight J.P. Morgan Cazenove
19.01.12 Holcim hold Deutsche Bank AG
19.01.12 Swiss Re buy Sarasin Research
19.01.12 ABB (Asea Brown Boveri) verkaufen National-Bank AG
19.01.12 ABB (Asea Brown Boveri) outperform Sanford C. Bernstein and Co., Inc.
19.01.12 UBS overweight Morgan Stanley
18.01.12 Holcim neutral Exane-BNP Paribas SA
18.01.12 UBS underperform Exane-BNP Paribas SA
18.01.12 UBS underperform Exane-BNP Paribas SA
18.01.12 Novartis halten Independent Research GmbH
18.01.12 Clariant hold Vontobel Research
18.01.12 SGS SA buy Vontobel Research
18.01.12 Tecan (N) hold Vontobel Research
18.01.12 Novartis hold Vontobel Research
17.01.12 Givaudan overweight J.P. Morgan Cazenove
17.01.12 Galenica neutral Sarasin Research